AstraZeneca to invest $2.5bn in Beijing R&D hub, biotech partnerships, and vaccine manufacturing
AstraZeneca is investing $2.5 billion in Beijing for R&D, biotech partnerships, and vaccine production. Learn how this move impacts its market strategy. Read More